Compare FEIM & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | ARVN |
|---|---|---|
| Founded | 1961 | 2015 |
| Country | United States | United States |
| Employees | N/A | 246 |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.9M | 600.2M |
| IPO Year | 1994 | 2018 |
| Metric | FEIM | ARVN |
|---|---|---|
| Price | $60.46 | $9.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 19 |
| Target Price | ★ $51.50 | $15.05 |
| AVG Volume (30 Days) | 228.0K | ★ 871.4K |
| Earning Date | 03-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | N/A | ★ 1.70 |
| Revenue | $63,227,000.00 | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.73 | N/A |
| P/E Ratio | ★ N/A | $5.44 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.05 | $6.97 |
| 52 Week High | $80.60 | $14.22 |
| Indicator | FEIM | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 43.61 | 51.84 |
| Support Level | $62.33 | $7.90 |
| Resistance Level | $64.99 | $9.65 |
| Average True Range (ATR) | 3.86 | 0.31 |
| MACD | -1.44 | -0.02 |
| Stochastic Oscillator | 20.33 | 31.07 |
Frequency Electronics Inc is a world leader in precision time and frequency generation technology, which is incorporated into commercial and U.S. Government satellites, Command, Control, Communication, Computer, Intelligence, Surveillance and Reconnaissance, and Electronic Warfare systems. Its technology is used for a wide range of space and non-space applications. The company has two segments FEI-NY, and FEI-Zyfer. Majority of revenue come from FEI-NY which provides precision time, frequency generation and synchronization products and subsystems that are found on-board satellites, in ground-based communication systems and imbedded in mobile platforms operated by the U.S. military.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.